Q1 Earnings Forecast for ICON Public Issued By William Blair

ICON Public Limited (NASDAQ:ICLR) – Equities researchers at William Blair issued their Q1 2026 EPS estimates for ICON Public in a research note issued on Thursday, February 20th. William Blair analyst M. Smock forecasts that the medical research company will earn $3.45 per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.38 per share. William Blair also issued estimates for ICON Public’s Q2 2026 earnings at $3.66 EPS, Q3 2026 earnings at $3.91 EPS, Q4 2026 earnings at $4.19 EPS and FY2026 earnings at $15.20 EPS.

A number of other analysts also recently issued reports on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $263.00 price target on shares of ICON Public in a report on Wednesday, January 15th. Barclays decreased their target price on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a research note on Friday, February 21st. Truist Financial lowered their price target on ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. Leerink Partners reiterated an “outperform” rating and set a $255.00 price objective (down previously from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Finally, Robert W. Baird dropped their target price on ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 20th. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $281.00.

ICON Public Trading Down 0.8 %

ICON Public stock opened at $197.50 on Monday. ICON Public has a one year low of $181.51 and a one year high of $347.72. The business’s fifty day moving average is $202.69 and its 200 day moving average is $242.86. The stock has a market capitalization of $16.29 billion, a PE ratio of 20.72, a price-to-earnings-growth ratio of 1.86 and a beta of 1.19. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.01. The business had revenue of $2.04 billion for the quarter, compared to analysts’ expectations of $2.04 billion. ICON Public had a return on equity of 11.81% and a net margin of 9.56%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ICLR. Sierra Ocean LLC purchased a new position in ICON Public during the fourth quarter valued at approximately $29,000. Park Place Capital Corp lifted its stake in shares of ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after buying an additional 166 shares in the last quarter. Private Trust Co. NA boosted its holdings in ICON Public by 48.8% in the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after buying an additional 82 shares during the period. GAMMA Investing LLC raised its holdings in ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares during the period. Finally, Horizon Investments LLC lifted its position in shares of ICON Public by 534.0% in the fourth quarter. Horizon Investments LLC now owns 653 shares of the medical research company’s stock valued at $137,000 after acquiring an additional 550 shares in the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.